Abbott study shows stroke reduction benefits of Amplatzer device

Abbott has announced the findings of a new clinical trial that demonstrates the stroke prevention benefits of its Amplatzer patent foramen ovale occluder device.

Long-term follow-up data from the landmark RESPECT trial showed that Amplatzer cut the risk of recurrent ischaemic stroke by 45 percent in patients with a hole in their heart compared to the standard of care medications.

The study involved 980 patients, with a median follow-up period of almost six years, and also found that Amplatzer reduced the risk of cryptogenic strokes by 62 percent among this patient group.

One in four people have a small opening between the upper left and right chambers of the heart, called a patent foramen ovale, that increases their risk for recurrent stroke. Amplatzer can address this risk over the course of a procedure that takes less than an hour and can be performed under conscious sedation.

Michael Dale, vice-president of Abbott's structural heart business, said the device "can help people with PFOs return to health and peace of mind, with a reduced risk of stroke, and without having to take daily medication for the condition".

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.